Sodium Hydroxide → alpha-[6-(1-Carboxy-3-phenylpropylamino)-2-(2-naphthyl)-5-oxoperhydro-1,4-thiazepin-4-yl]acetic acid

反応式

C([O:3][C:4]([CH:6]([NH:15][CH:16]1[CH2:22][S:21][CH:20]([C:23]2[CH:32]=[CH:31][C:30]3[C:25](=[CH:26][CH:27]=[CH:28][CH:29]=3)[CH:24]=2)[CH2:19][N:18]([CH2:33][C:34]([OH:36])=[O:35])[C:17]1=[O:37])[CH2:7][CH2:8][C:9]1[CH:14]=[CH:13][CH:12]=[CH:11][CH:10]=1)=[O:5])C.[OH-].[Na+]>>[C:4]([CH:6]([NH:15][CH:16]1[CH2:22][S:21][CH:20]([C:23]2[CH:32]=[CH:31][C:30]3[C:25](=[CH:26][CH:27]=[CH:28][CH:29]=3)[CH:24]=2)[CH2:19][N:18]([CH2:33][C:34]([OH:36])=[O:35])[C:17]1=[O:37])[CH2:7][CH2:8][C:9]1[CH:14]=[CH:13][CH:12]=[CH:11][CH:10]=1)([OH:5])=[O:3]

参加物

反応物 2

HCID 14798Sodium Hydroxide

HCID 20164862HCID 20164862、化合物

生成物 1

HCID 20164820alpha-[6-(1-Carboxy-3-phenylpropylamino)-2-(2-naphthyl)-5-oxoperhydro-1,4-thiazepin-4-yl]acetic acid収率 70.3%

実験手順

200 mg of α-[6-(1-ethoxycarbonyl-3-phenylpropylamino)-2-(2-naphthyl)-5-oxoperhydro-1,4-thiazepin-4-yl]acetic acid (prepared as described in Example 40 above) were hydrolyzed with aqueous sodium hydroxide in the same manner as described in Example 38, to give 133 mg of the title compound as a powder.

出典と根拠

ORDレコード: ord-1a777d6804814597b52bd7a66fe6ed92
出典データセット: uspto-grants-1987_10
DOI: 10.6084/m9.figshare.5104873.v1
特許番号: US04699905

反応ノート

読み込み中…